RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Han W, Liu M, Han D, Li M, et al. Oncogene 2022 Jan 3. pii: 10.1038/s41388-021-02135.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Han W, Liu M, Han D, Li M, et al. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Oncogene 2022 Jan 3. pii: 10.1038/s41388-021-02135.
PMID: 34975152